Shang-Hsuan Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shang-Hsuan Peng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Bor-Ching Sheu
Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan
1 shared publication - Ching-Hung Lin
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
1 shared publication Dwan‐Ying Chang
Department of Oncology National Taiwan University Hospital Taipei Taiwan
1 shared publication- Fu-Chang Hu
Graduate Institute of Clinical Medicine and School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan
1 shared publication - I-Chun Chen
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
1 shared publication - Kuan-Ju Huang
Department of Obstetrics and Gynecology, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan; Department of Obstetrics & Gynecology, National Taiwan University Hospital, Taipei, Taiwan
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Chao WT, et al. J Gynecol Oncol. 2026 ;37:e75. https://doi.org/10.3802/jgo.2026.37.e75
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Top Cited PapersOpen AccessPARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Chao WT, et al. J Gynecol Oncol. 2026 ;37:e75. https://doi.org/10.3802/jgo.2026.37.e75
- Open Access
- 22 September 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (19) , 20035-20051
Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis
Background: Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt.Methods: In this systematic review, phase 3 randomized controlled trials investigating pembrolizumab in advanced cancers and providing subgroup analyses of Asian and non‐Asian participants were included. The primary and secondary effect measures were the mean differences (MDs) in the natural logarithms of the hazard ratios (HRs) for overall survival (OS) and progression‐free survival (PFS) between these two subgroups, respectively. We used random‐effects meta‐analysis to calculate the pooled ratios of HRs (i.e., exp(MD)) and implemented a meta‐regression analysis to identify significant covariates.Results: A total of 17 and 11 trials were included in the meta‐analyses of OS and PFS, respectively. These trials included 2732 (25.49%) Asian and 7000 (65.32%) non‐Asian participants in the OS analysis and 1438 (22.5%) Asian and 4129 (64.61%) non‐Asian participants in the PFS analysis. The pooled ratio of HRs for OS was 0.87 (95% CI: 0.76–0.99; p = 0.0391), favoring Asian participants, but no significant difference was found in PFS (pooled ratio of HRs: 0.93; 95% CI: 0.82–1.07; p = 0.2391). Both linear meta‐regression analyses revealed an open‐label design as a crucial covariate, which indicated more benefits for non‐Asian participants.Conclusions: Compared with non‐Asian patients, Asian patients with advanced cancers may derive superior OS benefits from pembrolizumab. Although the results warrant further exploration, this meta‐analysis provides insight into clinical research design.
- 22 September 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (19) , 20035-20051
Open AccessDisparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis
Background: Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt.Methods: In this systematic review, phase 3 randomized controlled trials investigating pembrolizumab in advanced cancers and providing subgroup analyses of Asian and non‐Asian participants were included. The primary and secondary effect measures were the mean differences (MDs) in the natural logarithms of the hazard ratios (HRs) for overall survival (OS) and progression‐free survival (PFS) between these two subgroups, respectively. We used random‐effects meta‐analysis to calculate the pooled ratios of HRs (i.e., exp(MD)) and implemented a meta‐regression analysis to identify significant covariates.Results: A total of 17 and 11 trials were included in the meta‐analyses of OS and PFS, respectively. These trials included 2732 (25.49%) Asian and 7000 (65.32%) non‐Asian participants in the OS analysis and 1438 (22.5%) Asian and 4129 (64.61%) non‐Asian participants in the PFS analysis. The pooled ratio of HRs for OS was 0.87 (95% CI: 0.76–0.99; p = 0.0391), favoring Asian participants, but no significant difference was found in PFS (pooled ratio of HRs: 0.93; 95% CI: 0.82–1.07; p = 0.2391). Both linear meta‐regression analyses revealed an open‐label design as a crucial covariate, which indicated more benefits for non‐Asian participants.Conclusions: Compared with non‐Asian patients, Asian patients with advanced cancers may derive superior OS benefits from pembrolizumab. Although the results warrant further exploration, this meta‐analysis provides insight into clinical research design.